Krystal Biotech (KRYS) Cash & Current Investments (2016 - 2026)

Krystal Biotech's Cash & Current Investments history runs 11 years deep, the most recent figure standing at $823.4 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 33.49% year-over-year to $823.4 million; the TTM figure through Mar 2026 stood at $823.4 million (up 33.49% YoY), while the FY2025 annual figure was $827.8 million, up 38.54% from the prior year.
• Cash & Current Investments came in at $823.4 million for Q1 2026 at Krystal Biotech, down from $827.8 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $827.8 million in Q4 2025 to a low of $350.4 million in Q1 2023.
• A 5-year average of $560.0 million and a median of $559.6 million in 2024 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments declined 19.38% in 2023 and jumped 53.62% in 2024, its largest moves.
• Krystal Biotech's Cash & Current Investments stood at $379.2 million in 2022, then surged by 40.35% to $532.2 million in 2023, then climbed by 12.28% to $597.5 million in 2024, then soared by 38.54% to $827.8 million in 2025, then slipped by 0.53% to $823.4 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $823.4 million, $827.8 million, and $731.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison